Table 1.
Patient baseline characteristics
| Characteristic | Pomalidomide plus dexamethasone (N = 36) |
|---|---|
| Age | |
| Median (range), years | 64.5 (43–78) |
| >65 years, n (%) | 17 (47.2) |
| >75 years, n (%) | 4 (11.1) |
| Sex, n (%) | |
| Male | 16 (44.4) |
| Female | 20 (55.6) |
| Time from first diagnosis, median (range), years | 4.7 (0.6–21.1) |
| ECOG performance status, n (%) | |
| 0–1 | 33 (91.7) |
| 2 | 3 (8.3) |
| Durie–Salmon stage, n (%) | |
| I | 7 (19.4) |
| II | 16 (44.4) |
| III | 13 (36.1) |
| β2-microglobulin level, n (%) | |
| <3.5 mg/L | 24 (66.7) |
| 3.5–<5.5 mg/L | 10 (27.8) |
| ≥5.5 mg/L | 2 (5.6) |
| Bone lesions, n (%) | 22 (61.1) |
| Extramedullary plasmacytoma, n (%) | 5 (13.9) |
| Creatinine clearance, n (%) | |
| <30 mL/min | 0 |
| 30–<45 mL/min | 0 |
| 45–<60 mL/min | 8 (22.2) |
| 60–<80 mL/min | 13 (36.1) |
| ≥80 mL/min | 15 (41.7) |
| Prior antimyeloma therapies, median (range) | 6.5 (2–15) |
| Prior stem cell transplant, n (%) | 19 (52.8) |
| Prior therapies, n (%) | |
| Lenalidomide | 36 (100.0) |
| Bortezomib | 36 (100.0) |
| Thalidomide | 12 (33.3) |
| Dexamethasone | 35 (97.2) |
| Melphalan | 31 (86.1) |
| Last prior therapy, n (%) | |
| Lenalidomide | 21 (58.3) |
| Bortezomib | 15 (41.7) |
| Refractory to prior therapies, n (%) | |
| Lenalidomide | 35 (97.2) |
| Bortezomib | 21 (58.3) |
| Both lenalidomide and bortezomib | 21 (58.3) |
ECOG Eastern Cooperative Oncology Group